Literature DB >> 27885272

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

F Passamonti1, B Mora1, T Giorgino2, P Guglielmelli3, M Cazzola4, M Maffioli1, A Rambaldi4, M Caramella5, R Komrokji6, J Gotlib7, J J Kiladjian8, F Cervantes9, T Devos10, F Palandri11, V De Stefano12, M Ruggeri13, R Silver14, G Benevolo15, F Albano16, D Caramazza1, E Rumi4, M Merli1, D Pietra4, R Casalone17, T Barbui18, L Pieri2, A M Vannucchi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27885272     DOI： 10.1038/leu.2016.351

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

2.  CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Authors:  M C Finazzi; A Carobbio; F Cervantes; I M Isola; A M Vannucchi; P Guglielmelli; A Rambaldi; G Finazzi; G Barosi; T Barbui
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

3.  The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Montse Gómez; Concepción Boqué; Francisca Ferrer-Marín; José-María Raya; Valentín García-Gutiérrez; Ana Kerguelen; Blanca Xicoy; Pere Barba; Jesús Martínez; Elisa Luño; Alberto Alvarez-Larrán; Joaquín Martínez-López; Elisa Arbelo; Carles Besses
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

4.  Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.

Authors:  Yoseph C Elala; Terra L Lasho; Naseema Gangat; Christy Finke; Daniela Barraco; Mahnur Haider; Ahmed K Abou Hussein; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

8.  Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.

Authors:  Giada Rotunno; Annalisa Pacilli; Valentina Artusi; Elisa Rumi; Margherita Maffioli; Federica Delaini; Giada Brogi; Tiziana Fanelli; Alessandro Pancrazzi; Daniela Pietra; Isabella Bernardis; Clara Belotti; Lisa Pieri; Emanuela Sant'Antonio; Silvia Salmoiraghi; Daniela Cilloni; Alessandro Rambaldi; Francesco Passamonti; Tiziano Barbui; Rossella Manfredini; Mario Cazzola; Enrico Tagliafico; Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Am J Hematol       Date:  2016-05-11       Impact factor: 10.047

9.  Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.

Authors:  Yan Beauverd; Samah Alimam; Donal P McLornan; Deepti H Radia; Claire N Harrison
Journal:  Br J Haematol       Date:  2016-06-13       Impact factor: 6.998

10.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528
View more
  14 in total

Review 1.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

2.  Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Authors:  Barbara Mora; Toni Giorgino; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Barraco; Michele Merli; Daniela Pietra; Rosario Casalone; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Francesco Passamonti
Journal:  Haematologica       Date:  2018-04-05       Impact factor: 9.941

3.  Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.

Authors:  Kyohei Misawa; Hajime Yasuda; Marito Araki; Tomonori Ochiai; Soji Morishita; Shuichi Shirane; Yoko Edahiro; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2018-02-20       Impact factor: 2.490

Review 4.  Mutational profiling in myelofibrosis: implications for management.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2019-10-19       Impact factor: 2.490

5.  Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.

Authors:  Barbara Mora; Paola Guglielmelli; Andrew Kuykendall; Elisa Rumi; Margherita Maffioli; Francesca Palandri; Valerio De Stefano; Marianna Caramella; Silvia Salmoiraghi; Jean-Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Marco Ruggeri; Richard T Silver; Francesco Albano; Giulia Benevolo; David M Ross; Matteo G Della Porta; Timothy Devos; Giada Rotunno; Rami S Komrokji; Ilaria C Casetti; Michele Merli; Marco Brociner; Domenica Caramazza; Giuseppe Auteri; Tiziano Barbui; Daniele Cattaneo; Lorenza Bertù; Luca Arcaini; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Leukemia       Date:  2022-08-30       Impact factor: 12.883

Review 6.  Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Authors:  Francesco Passamonti; Barbara Mora; Daniela Barraco; Margherita Maffioli
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

7.  Therapy of polycythemia vera: is it time to change?

Authors:  Francesco Passamonti; Margherita Maffioli; Barbara Mora
Journal:  Oncotarget       Date:  2017-11-03

Review 8.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26

9.  Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Authors:  Daniela Barraco; Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Michele Merli; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Toni Giorgino; Alessandro Maria Vannucchi; Francesco Passamonti
Journal:  Blood Cancer J       Date:  2018-09-21       Impact factor: 11.037

10.  t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma.

Authors:  Kalyan Nadiminti; Margarida Silverman; Sharathkumar Bhagavathi; Praveen Vikas
Journal:  Onco Targets Ther       Date:  2019-07-11       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.